Analgesics, also called painkillers, are medications that relieve different types of pain 鈥� from headaches to injuries to arthritis.听Anti-inflammatory analgesics reduce inflammation, and opioid analgesics change the way the brain perceives pain.
The global market for Analgesic and Anti-inflammatory API was estimated to be worth US$ 702 million in 2023 and is forecast to a readjusted size of US$ 930.3 million by 2030 with a CAGR of 4.1% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Analgesic and Anti-inflammatory API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Analgesic and Anti-inflammatory API by region & country, by Type, and by Application.
The Analgesic and Anti-inflammatory API market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Analgesic and Anti-inflammatory API.
麻豆原创 Segmentation
By Company
IOL
Mallinckrodt Pharmaceuticals
Anqiu Lu'an Pharmaceutical
Novacyl
BASF
BBCA Group
Hubei Biocause Group
Xinhua Pharm
Granules India Limited
Hebei Jiheng Pharmaceutical
Zhejiang Kangle Pharmaceutical
Hunan Zhongnan Pharmaceutical
Hebei Jingye Medical Technology
Segment by Type:
Ibuprofen
Paracetamol
Aspirin
Naproxen
Diclofenac
Oxaprozin
Dexibuprofen
Others
Segment by Application
Adults
Children
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Analgesic and Anti-inflammatory API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Analgesic and Anti-inflammatory API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Analgesic and Anti-inflammatory API in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Analgesic and Anti-inflammatory API Product Introduction
1.2 Global Analgesic and Anti-inflammatory API 麻豆原创 Size Forecast
1.2.1 Global Analgesic and Anti-inflammatory API Sales Value (2019-2030)
1.2.2 Global Analgesic and Anti-inflammatory API Sales Volume (2019-2030)
1.2.3 Global Analgesic and Anti-inflammatory API Sales Price (2019-2030)
1.3 Analgesic and Anti-inflammatory API 麻豆原创 Trends & Drivers
1.3.1 Analgesic and Anti-inflammatory API Industry Trends
1.3.2 Analgesic and Anti-inflammatory API 麻豆原创 Drivers & Opportunity
1.3.3 Analgesic and Anti-inflammatory API 麻豆原创 Challenges
1.3.4 Analgesic and Anti-inflammatory API 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Analgesic and Anti-inflammatory API Players Revenue Ranking (2023)
2.2 Global Analgesic and Anti-inflammatory API Revenue by Company (2019-2024)
2.3 Global Analgesic and Anti-inflammatory API Players Sales Volume Ranking (2023)
2.4 Global Analgesic and Anti-inflammatory API Sales Volume by Company Players (2019-2024)
2.5 Global Analgesic and Anti-inflammatory API Average Price by Company (2019-2024)
2.6 Key Manufacturers Analgesic and Anti-inflammatory API Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Analgesic and Anti-inflammatory API Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Analgesic and Anti-inflammatory API
2.9 Analgesic and Anti-inflammatory API 麻豆原创 Competitive Analysis
2.9.1 Analgesic and Anti-inflammatory API 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Analgesic and Anti-inflammatory API Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Analgesic and Anti-inflammatory API as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Ibuprofen
3.1.2 Paracetamol
3.1.3 Aspirin
3.1.4 Naproxen
3.1.5 Diclofenac
3.1.6 Oxaprozin
3.1.7 Dexibuprofen
3.1.8 Others
3.2 Global Analgesic and Anti-inflammatory API Sales Value by Type
3.2.1 Global Analgesic and Anti-inflammatory API Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Analgesic and Anti-inflammatory API Sales Value, by Type (2019-2030)
3.2.3 Global Analgesic and Anti-inflammatory API Sales Value, by Type (%) (2019-2030)
3.3 Global Analgesic and Anti-inflammatory API Sales Volume by Type
3.3.1 Global Analgesic and Anti-inflammatory API Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Analgesic and Anti-inflammatory API Sales Volume, by Type (2019-2030)
3.3.3 Global Analgesic and Anti-inflammatory API Sales Volume, by Type (%) (2019-2030)
3.4 Global Analgesic and Anti-inflammatory API Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Adults
4.1.2 Children
4.2 Global Analgesic and Anti-inflammatory API Sales Value by Application
4.2.1 Global Analgesic and Anti-inflammatory API Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Analgesic and Anti-inflammatory API Sales Value, by Application (2019-2030)
4.2.3 Global Analgesic and Anti-inflammatory API Sales Value, by Application (%) (2019-2030)
4.3 Global Analgesic and Anti-inflammatory API Sales Volume by Application
4.3.1 Global Analgesic and Anti-inflammatory API Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Analgesic and Anti-inflammatory API Sales Volume, by Application (2019-2030)
4.3.3 Global Analgesic and Anti-inflammatory API Sales Volume, by Application (%) (2019-2030)
4.4 Global Analgesic and Anti-inflammatory API Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Analgesic and Anti-inflammatory API Sales Value by Region
5.1.1 Global Analgesic and Anti-inflammatory API Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Analgesic and Anti-inflammatory API Sales Value by Region (2019-2024)
5.1.3 Global Analgesic and Anti-inflammatory API Sales Value by Region (2025-2030)
5.1.4 Global Analgesic and Anti-inflammatory API Sales Value by Region (%), (2019-2030)
5.2 Global Analgesic and Anti-inflammatory API Sales Volume by Region
5.2.1 Global Analgesic and Anti-inflammatory API Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Analgesic and Anti-inflammatory API Sales Volume by Region (2019-2024)
5.2.3 Global Analgesic and Anti-inflammatory API Sales Volume by Region (2025-2030)
5.2.4 Global Analgesic and Anti-inflammatory API Sales Volume by Region (%), (2019-2030)
5.3 Global Analgesic and Anti-inflammatory API Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Analgesic and Anti-inflammatory API Sales Value, 2019-2030
5.4.2 North America Analgesic and Anti-inflammatory API Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Analgesic and Anti-inflammatory API Sales Value, 2019-2030
5.5.2 Europe Analgesic and Anti-inflammatory API Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Analgesic and Anti-inflammatory API Sales Value, 2019-2030
5.6.2 Asia Pacific Analgesic and Anti-inflammatory API Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Analgesic and Anti-inflammatory API Sales Value, 2019-2030
5.7.2 South America Analgesic and Anti-inflammatory API Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Analgesic and Anti-inflammatory API Sales Value, 2019-2030
5.8.2 Middle East & Africa Analgesic and Anti-inflammatory API Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Analgesic and Anti-inflammatory API Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Analgesic and Anti-inflammatory API Sales Value
6.2.1 Key Countries/Regions Analgesic and Anti-inflammatory API Sales Value, 2019-2030
6.2.2 Key Countries/Regions Analgesic and Anti-inflammatory API Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Analgesic and Anti-inflammatory API Sales Value, 2019-2030
6.3.2 United States Analgesic and Anti-inflammatory API Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Analgesic and Anti-inflammatory API Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Analgesic and Anti-inflammatory API Sales Value, 2019-2030
6.4.2 Europe Analgesic and Anti-inflammatory API Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Analgesic and Anti-inflammatory API Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Analgesic and Anti-inflammatory API Sales Value, 2019-2030
6.5.2 China Analgesic and Anti-inflammatory API Sales Value by Type (%), 2023 VS 2030
6.5.3 China Analgesic and Anti-inflammatory API Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Analgesic and Anti-inflammatory API Sales Value, 2019-2030
6.6.2 Japan Analgesic and Anti-inflammatory API Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Analgesic and Anti-inflammatory API Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Analgesic and Anti-inflammatory API Sales Value, 2019-2030
6.7.2 South Korea Analgesic and Anti-inflammatory API Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Analgesic and Anti-inflammatory API Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Analgesic and Anti-inflammatory API Sales Value, 2019-2030
6.8.2 Southeast Asia Analgesic and Anti-inflammatory API Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Analgesic and Anti-inflammatory API Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Analgesic and Anti-inflammatory API Sales Value, 2019-2030
6.9.2 India Analgesic and Anti-inflammatory API Sales Value by Type (%), 2023 VS 2030
6.9.3 India Analgesic and Anti-inflammatory API Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 IOL
7.1.1 IOL Company Information
7.1.2 IOL Introduction and Business Overview
7.1.3 IOL Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.1.4 IOL Analgesic and Anti-inflammatory API Product Offerings
7.1.5 IOL Recent Development
7.2 Mallinckrodt Pharmaceuticals
7.2.1 Mallinckrodt Pharmaceuticals Company Information
7.2.2 Mallinckrodt Pharmaceuticals Introduction and Business Overview
7.2.3 Mallinckrodt Pharmaceuticals Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Mallinckrodt Pharmaceuticals Analgesic and Anti-inflammatory API Product Offerings
7.2.5 Mallinckrodt Pharmaceuticals Recent Development
7.3 Anqiu Lu'an Pharmaceutical
7.3.1 Anqiu Lu'an Pharmaceutical Company Information
7.3.2 Anqiu Lu'an Pharmaceutical Introduction and Business Overview
7.3.3 Anqiu Lu'an Pharmaceutical Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Anqiu Lu'an Pharmaceutical Analgesic and Anti-inflammatory API Product Offerings
7.3.5 Anqiu Lu'an Pharmaceutical Recent Development
7.4 Novacyl
7.4.1 Novacyl Company Information
7.4.2 Novacyl Introduction and Business Overview
7.4.3 Novacyl Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Novacyl Analgesic and Anti-inflammatory API Product Offerings
7.4.5 Novacyl Recent Development
7.5 BASF
7.5.1 BASF Company Information
7.5.2 BASF Introduction and Business Overview
7.5.3 BASF Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.5.4 BASF Analgesic and Anti-inflammatory API Product Offerings
7.5.5 BASF Recent Development
7.6 BBCA Group
7.6.1 BBCA Group Company Information
7.6.2 BBCA Group Introduction and Business Overview
7.6.3 BBCA Group Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.6.4 BBCA Group Analgesic and Anti-inflammatory API Product Offerings
7.6.5 BBCA Group Recent Development
7.7 Hubei Biocause Group
7.7.1 Hubei Biocause Group Company Information
7.7.2 Hubei Biocause Group Introduction and Business Overview
7.7.3 Hubei Biocause Group Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Hubei Biocause Group Analgesic and Anti-inflammatory API Product Offerings
7.7.5 Hubei Biocause Group Recent Development
7.8 Xinhua Pharm
7.8.1 Xinhua Pharm Company Information
7.8.2 Xinhua Pharm Introduction and Business Overview
7.8.3 Xinhua Pharm Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Xinhua Pharm Analgesic and Anti-inflammatory API Product Offerings
7.8.5 Xinhua Pharm Recent Development
7.9 Granules India Limited
7.9.1 Granules India Limited Company Information
7.9.2 Granules India Limited Introduction and Business Overview
7.9.3 Granules India Limited Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Granules India Limited Analgesic and Anti-inflammatory API Product Offerings
7.9.5 Granules India Limited Recent Development
7.10 Hebei Jiheng Pharmaceutical
7.10.1 Hebei Jiheng Pharmaceutical Company Information
7.10.2 Hebei Jiheng Pharmaceutical Introduction and Business Overview
7.10.3 Hebei Jiheng Pharmaceutical Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Hebei Jiheng Pharmaceutical Analgesic and Anti-inflammatory API Product Offerings
7.10.5 Hebei Jiheng Pharmaceutical Recent Development
7.11 Zhejiang Kangle Pharmaceutical
7.11.1 Zhejiang Kangle Pharmaceutical Company Information
7.11.2 Zhejiang Kangle Pharmaceutical Introduction and Business Overview
7.11.3 Zhejiang Kangle Pharmaceutical Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Zhejiang Kangle Pharmaceutical Analgesic and Anti-inflammatory API Product Offerings
7.11.5 Zhejiang Kangle Pharmaceutical Recent Development
7.12 Hunan Zhongnan Pharmaceutical
7.12.1 Hunan Zhongnan Pharmaceutical Company Information
7.12.2 Hunan Zhongnan Pharmaceutical Introduction and Business Overview
7.12.3 Hunan Zhongnan Pharmaceutical Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Hunan Zhongnan Pharmaceutical Analgesic and Anti-inflammatory API Product Offerings
7.12.5 Hunan Zhongnan Pharmaceutical Recent Development
7.13 Hebei Jingye Medical Technology
7.13.1 Hebei Jingye Medical Technology Company Information
7.13.2 Hebei Jingye Medical Technology Introduction and Business Overview
7.13.3 Hebei Jingye Medical Technology Analgesic and Anti-inflammatory API Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Hebei Jingye Medical Technology Analgesic and Anti-inflammatory API Product Offerings
7.13.5 Hebei Jingye Medical Technology Recent Development
8 Industry Chain Analysis
8.1 Analgesic and Anti-inflammatory API Industrial Chain
8.2 Analgesic and Anti-inflammatory API Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Analgesic and Anti-inflammatory API Sales Model
8.5.2 Sales Channel
8.5.3 Analgesic and Anti-inflammatory API Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
IOL
Mallinckrodt Pharmaceuticals
Anqiu Lu'an Pharmaceutical
Novacyl
BASF
BBCA Group
Hubei Biocause Group
Xinhua Pharm
Granules India Limited
Hebei Jiheng Pharmaceutical
Zhejiang Kangle Pharmaceutical
Hunan Zhongnan Pharmaceutical
Hebei Jingye Medical Technology
听
听
*If Applicable.
